1. Background {#s0005}
=============

Kawasaki disease (KD) is an acute systemic vasculitis complicated by coronary aneurysms that predominantly occurs in young East Asian children. Typical symptoms include fever for more than 5 days, exanthema, lymphadenopathy, conjunctival injection, altered oropharyngeal mucosa, and extremity changes. The etiology of KD remains uncertain and cases remain rare ([@bb0030]). Nevertheless, an upsurge of KD cases in Europe was observed during the Coronavirus Disease 2019 (COVID-19) pandemic. Out of the 10 KD cases reported in children from Bergamo, Italy, 2 tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by PCR, whereas 8 tested positive for SARS-CoV-2 antibodies ([@bb0095]). A similar cluster of KD cases in children was reported in France during the outbreak, in which 14 children tested positive for SARS-CoV-2 IgG, but only 7 children tested positive for SARS-CoV-2 by PCR. As KD is known to be more prevalent in Hong Kong than in Europe ([@bb0080]; [@bb0045]) and Hong Kong was close to the epicenter of the initial COVID-19 outbreak, concerns have been raised about new cases of KD in Hong Kong children during the outbreak and whether they were associated with SARS-CoV-2 infection. Therefore, serological testing for SARS-CoV-2 was offered to Hong Kong children diagnosed with KD between January and April 2020.

2. Objective {#s0010}
============

We aim to describe 3 pediatric Kawasaki Disease patients diagnosed during the COVID-19 outbreak with false positive SARS-CoV-2 serology.

3. Methods {#s0015}
==========

Children diagnosed with KD between January and April 2020 were identified. Their clinical and laboratory data were reviewed. Serological testing was performed to determine possible exposures to SARS-CoV-2. This study was approved by the University of Hong Kong/Hospital Authority Hong Kong West Cluster Institutional Review Board (Reference number: UW 20-292). Written consent was obtained from parents prior to testing.

3.1. Real-time reverse transcription polymerase chain reaction (RT-PCR) assays for SARS-CoV-2 RNA testing of respiratory specimens {#s0020}
----------------------------------------------------------------------------------------------------------------------------------

Nasaopharyngeal swabs (NPS) obtained during admission were tested by RT-PCR using the LightMix® Modular SARS and Wuhan CoV E-gene kit (TIB Molbiol, Berlin, Germany) on a LightCycler Multiplex RNA Virus Master (Roche, Penzberg, Germany) according to the manufacturer's instructions.

3.2. Detection of IgG against SARS-CoV-2 nucleoprotein and spike protein receptor binding domain {#s0025}
------------------------------------------------------------------------------------------------

Blood (5 mL) was collected from each patient and serum was obtained for the detection of IgG against SARS-CoV-2 nucleoprotein (NP) and spike protein receptor binding domain (RBD) using a microsphere-based antibody assay as described previously ([@bb0010]). IgM was not measured in this assay. Briefly, cloning and purification of SARS-CoV-2 NP and spike RBD were performed as described previously ([@bb0060], [@bb0070]). Both proteins were biotinylated using EZ-link^TM^ Sulfo-NHS-Biotin (ThermoFisher Scientific, MA, USA). SuperAvidinTM coated microspheres (Bangs Laboratories, Indiana, USA) were coated with biotinylated NP or spike RBD and then mixed with serum at a dilution of 1:400. Bound antibodies were detected with Alexa Fluor ® 647 AffinPure Fab fragment goat anti-human IgG. Flow cytometry was performed on a BD LSR Fortessa analyzer (BD Biosciences, San Jose, CA, USA) and data were analyzed using FlowJo v10.6.2 (FlowJo LLC, Ashland, OR, USA).

3.3. Microneutralization (MN) assay {#s0030}
-----------------------------------

Virus culture and MN assay were performed as previously described ([@bb0070], [@bb0065]). Briefly, serum samples (50 μL) were prepared in minimum essential medium and mixed with SARS-CoV-2 (50 μL) to give a serum dilution of 1:10 and a final virus inoculum of 100 TCID~50~. The serum-virus mixture was incubated at 37 °C for 1 hour and then added to VeroE6 cells and incubated at 37 °C and 5% CO~2~ for 72 hours. Cytopathic effects were determined under inversion microscopy. The MN antibody titer was determined as the highest dilution showing 50% inhibition of CPE. An MN titer ≥10 was considered positive as described previously ([@bb0050]).

4. Results {#s0035}
==========

Three Chinese children, who had no epidemiological links with COVID-19 patients were diagnosed with typical KD during the peak of COVID-19 outbreak in Hong Kong ([Table 1](#t0005){ref-type="table"} ). They were tested negative for SARS-CoV-2 and other common respiratory pathogens in nasopharyngeal aspirate polymerase chain reaction (PCR), including respiratory syncitial virus, adenovirus, human metapneumovirus, influenza A and B, parainfluenza virus type 1, 2, 3, 4, rhinovirus, bocavirus, enterovirus, coronavirus 229E, NL63, HKU1, and OC43, *Bordetella pertussis*, *Bordetella parapertussis*, *Chlamydia pneumoniae* and *Mycoplasma pneumoniae*. They achieved complete recovery with one dose of intravenous immunoglobulins at 2g/kg, high-dose aspirin at 30--50 mg/kg per day until 2 days after defervescence, followed by low-dose aspirin at 3--5 mg/kg per day for 8 weeks. In view of the possible association between KD and COVID-19 infection, they were called back to test for SARS-CoV-2 anti-NP and anti-RBD antibodies 60--90 days after the diagnosis of KD. Patient 1 tested positive for SARS-CoV-2 anti-RBD IgG, whereas both patients 2 and 3 tested positive for SARS-CoV-2 anti-NP and anti-RBD IgG. However, all 3 patients tested negative with the microneutralization assay, suggesting that the IgG results were false positives.Table 1Summary of 3 Chinese Kawasaki Disease patients with false positive SARS-CoV-2 serology.Table 1No.Age/\
GenderSignificant Past HealthCOVID-19 ContactSymptomsRespiratory Virus PCR[\#](#tf0010){ref-type="table-fn"}SARS-CoV-2 PCR[%](#tf0015){ref-type="table-fn"}EchoSerology (Number of Days taken after IVIG)MNTreatmentOutcome13 months/FNoneNone • Rhinorrhea\
 • Blocked Nose\
 • 7 days of fever\
 • Conjunctivitis\
 • Cracked lips\
 • MP rashNegativeNegativePerivascular echogenicity and non-tapering coronary arteriesAnti-RBD IgG positive\
(90 days)NegativeIVIG 2 g/kg\
Aspirin[⁎](#tf0005){ref-type="table-fn"}Resolution of fever and KD features. Normal coronary arteries at 12-week follow-up.26 months/FNoneNone • Cough\
 • Rhinorrhea\
 • 6 days of fever\
 • Conjunctivitis\
 • MP rash\
 • Erythematous lipsEV/RVNegativePerivascular echogenicity and non-tapering coronary arteriesAnti-RBD and anti-NP IgG positive\
(87 days)NegativeIVIG 2 g/kg\
Aspirin[⁎](#tf0005){ref-type="table-fn"}Resolution of fever and KD features.\
Normal coronary arteries at 8-week follow-up.33 months/MNoneNone • 5 days of fever\
 • Cough and\
 • Rhinorrhoea\
 • Conjunctivitis\
 • Cervical lymphadenopathy\
 • MP rash\
 • Erythematous Lips\
 • Swelling of hands\
and feet\
 • Erythema of BCG\
scarNegativeNegativeNormalAnti-RBD and anti-NP IgG positive\
(60 days)NegativeIVIG 2 g/kg\
Aspirin[⁎](#tf0005){ref-type="table-fn"}Resolution of fever and KD features.\
Normal coronary arteries at 2-week follow-up.[^2][^3][^4][^5]

5. Discussion {#s0040}
=============

To the best of our knowledge, this is the first report demonstrating false-positive SARS-CoV-2 serology among KD children. The 3 patients reported in this study did not report any epidemiological links to individuals with COVID-19 or any travel history in areas with COVID-19 outbreaks. They did not report any symptoms or signs of SARS-CoV-2 infection prior to admission for KD. Only SARS-CoV-2 anti-RBD IgG was detected in 1 patient, whereas both anti-RBD and anti-NP IgG were detected in 2 patients. However, no neutralizing antibodies were detected in any of the patients by MN assay, suggesting the antibodies detected in the serology assay were unlikely to be related to a prior SARS-CoV-2 infection. The serological assay used in this study has sensitivity of 89.8% for ant-NP IgG and 79.5% for anti-RBD IgG, as well as specificity of 100% for anti-NP IgG and 98.9% for anti-RBD IgG when evaluated using sera collected from influenza patients or organ donors before 2020 ([@bb0010]). The false-positive results from the serological testing could possibly be due to the presence of cross-reactive antibodies elicited by other triggers, such as non-specific antibodies triggered by Kawasaki Disease reacting to NP, RBD or any reagents in the blocking buffer; or cross-reactive antibodies triggered by other coronaviruses. False-positive results have been well reported in serological testing for immune responses against viral infections, such as false positives in hepatitis A and cytomegalovirus serologies from Epstein-Barr virus infection ([@bb0035]; [@bb0085]). We believe the false positive SARS-CoV-2 serology results were unrelated to the administration of IVIG for treating KD. First, the time interval between IVIG administration and serology testing ranged between 60 and 90 days, whereas the median half-life of IVIG is 21 days ([@bb0020]). Second, the IVIG treatment, Intragam® P (CSL Behring Asia Pacific Limited), was manufactured from the pooled plasma of healthy Hong Kong blood donors and had been made months before its use ([@bb0005]), and therefore unlikely to contain any plasma from donors with COVID-19, as the first case of COVID-19 was diagnosed in Hong Kong in late January 2020 ([@bb0025]).

The association between KD and COVID-19 remains unclear. To date, a total of 4 case series and reports on 40 patients have proposed a possible link between COVID-19 and KD ([@bb0015]; [@bb0090]; [@bb0075]; [@bb0055]). Although 11 patients were confirmed to have COVID-19 by a positive SARS-CoV-2 PCR in respiratory specimens, the other patients were reported to have positive SARS-CoV-2 serology without confirmation by microneutralization assay ([Table 2](#t0010){ref-type="table"} ). Thus, the possibility that these patients might have false positive results cannot be ruled out. Clinically, not all the patients in these case series presented with KD symptoms reported in cases in Asia, which typically involved younger children under 4 years and commonly included symptoms such as erythema and swelling of BCG scars ([@bb0040]). Epidemiologically, there was a 30-fold increase in the monthly incidence of KD in Italy during the COVID-19 pandemic, whereas the incidence of KD in Hong Kong remained the same (unpublished data). Furthermore, we reviewed all NPS samples from KD patients admitted to public hospitals in Hong Kong, which were all negative for SARS-CoV-2 PCR. Data from Wuhan Children's Hospital in China reported 244 children with COVID-19, but none showed any symptoms and signs of KD (submitted and under review). Large-scale observational studies are needed to determine whether the reported cases belong to classical KD or another form of hyperinflammatory disease, recently termed pediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 (PIMS-TS). Frontline clinicians should be aware of the potential false-positive IgG results. Patients with positive SARS-CoV-2 serology but negative PCR should be further tested by MN assay for the presence of neutralizing antibodies.Table 2Summary of case series and reports on Kawasaki Disease possibly associated with SARS-CoV-2 infection.Table 2Study/CountryNo. of Cases ReportedAge Range (years)Parents\' EthnicityDiagnosesIgG assayNo. of cases with suspected or confirmed COVID-19 contactNo. of cases with positive respiratory pathogens from respiratory specimenNo. of cases with positive SARS-CoV-2 RT-PCR from respiratory specimenNo. of cases with positive SARS-CoV-2 IgMNo. of cases with positive SARS-CoV-2 IgGWas MN assay performed?([@bb0015])/USA10.5N/ATypical KDNot done001N/AN/AN/A([@bb0090])/Italy102.9--16N/A5 typical KD\
5 KDSSLateral flow chromatographic immunoassay50238No([@bb0075])/France213.7--16.6Sub-Saharan Africa/Caribbean islands\
Asian\
European\
Middle East11 typical KD\
10 incomplete KD\
12 KDSSArchitect SARS-CoV-2 chemiluminescent microparticle immunoassay1008N/A19No([@bb0055])/UK86--14Afro-CaribbeanAll considered as atypical KD, KDSS or toxic shock syndromeN/A41 (Adenovirus, enterovirus)02 were antibody positive (no mention of whether IgM or IgG)No[^6]
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[^1]: Co-first authors.

[^2]: Echo = echocardiogram, EV/RV = enterovirus/rhinovirus, IVIG = intravenous immunoglobulin, MN = microneutralization assay, MP = maculopapular, NP = nucleoprotein, RBD = receptor binding domain.

[^3]: Initial high-dose aspirin at 30--50 mg/kg per day until 2 days after defervescence, followed by low-dose aspirin at 3--5 mg/kg per day for 8 weeks.

[^4]: Nasopharyngeal swab specimen.

[^5]: Pooled nasopharyngeal and throat swab specimens.

[^6]: COVID-19 = Coronavirus Disease 2019, KD = Kawasaki Disease, KDSS = Kawasaki Disease Shock Syndrome, MN = Microneutralization assay, N/A = not available, RT-PCR = reverse transcription polymerase chain reaction, SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.
